PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

NCI-MATCH cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment

Trastuzumab-pertuzumab is FDA-approved for patients with HER2-positive breast cancer, with minimal side effects. The NCI-MATCH precision medicine trial saw it shrink tumors in several other cancer types—a discovery that warrants further research.

NCI-MATCH cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment
2024-03-04
(Press-News.org) An important discovery from the NCI-MATCH precision medicine initiative is being published today in Clinical Cancer Research, a journal of the American Association for Cancer Research. Trastuzumab-pertuzumab, a drug combination approved by the US Food and Drug Administration (FDA) to treat patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, shrunk tumors in patients with several other types of cancer with high levels of the HER2 gene. NCI-MATCH (Molecular Analysis for Therapy Choice) is one of the first and largest precision oncology trials ever undertaken globally.

NCI-MATCH Arm J was a single-arm phase 2 trial in patients with advanced (metastatic) HER2-amplified cancers other than breast cancer. The study also excluded patients with gastric (stomach) cancer or gastroesophageal junction adenocarcinoma, where there is another approved targeted therapy. HER2 receptors control how cells grow and divide.

“This was an extremely important study based on the established efficacy benefits of the trastuzumab-pertuzumab combination in HER2-positive breast cancer. We found that select patients with other cancer types with high levels of HER2 amplification benefitted from this approach, which is associated with minimal side effects,” said lead investigator Roisin M. Connolly, MB, BCh, MD, of University College Cork in Ireland, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN).

The development of resistance to trastuzumab is a common clinical challenge, leading to numerous clinical trials seeking improvements for patients.

“It is so important for us to identify treatment approaches that result in high rates of tumor shrinkage while minimizing adverse effects for the patients and maximizing quality of life during the treatment course,” said Dr. Connolly.

Eligible patients for NCI-MATCH Arm J had high levels of HER2 amplification, defined as a copy number of seven or more. The study enrolled 35 patients, and the primary analysis included 25 based on central evaluation of HER2 amplification. The median age was 66 (range 31-80), 56% were female, and half had three or more prior therapies (range 1-11). The cancer types were gynecologic (11), gastrointestinal (11), urinary bladder (2), and head and neck (1).

“As a number of patients in Arm J had shrinkage of their cancers with this dual HER2 blockade, it is clear that select patients with this genomic aberration may benefit from HER2 pathway blockade,” Dr. Connolly explained.

The confirmed overall response rate (ORR) in evaluable patients was 12% (3/25 patients). All three patients had a partial response. They each had a different cancer: adenocarcinoma of the rectum, cholangiocarcinoma, and transitional cell carcinoma of the bladder.

There was one additional partial response in a patient with urothelial cancer and an unconfirmed HER2 copy number. Stable disease was observed in another nine patients with cholangiocarcinoma, gynecologic, and colorectal cancers. The trial came just short of meeting the predefined success criteria for the primary endpoint (defined as an ORR greater than 16% or 4/25 patients).

“As the prespecified criteria for efficacy success was not met, it may be that more refined patient selection, such as predictive biomarkers, or alternative HER2-directed approaches, such as combinations with chemotherapy, or newer antibody drug conjugates, may help a larger proportion of patients,” she said.

The NCI sponsored the trial. The manufacturer, Genentech, a member of the Roche Group, supplied trastuzumab-pertuzumab for the trial through a Clinical Trial Participation Agreement with NCI.

Trastuzumab and Pertuzumab in Patients with non-Breast/Gastroesophageal HER2-amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. 

 

About NCI-MATCH

NCI-MATCH is a large precision medicine basket trial that enrolled patients with advanced cancer into 38 single-arm phase 2 subprotocols (treatment arms) based on genomic alterations in tumor tissue. ECOG-ACRIN designed and led NCI-MATCH with the National Cancer Institute (NCI), part of the National Institutes of Health, and with the participation of the NCI National Clinical Trials Network (NCTN). Many of the treatment arms are completed and have published results. Learn more at www.ecog-acrin.org/nci-match.

 

About ECOG-ACRIN 

The ECOG-ACRIN Cancer Research Group is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. The Group comprises nearly 1400 member institutions and 21,000 research professionals in the United States and around the world. For more information, visit ecog-acrin.org, follow us on X/Twitter @eaonc, Facebook, LinkedIn, and Instagram, or call 215.789.3631. 

END

[Attachments] See images for this press release:
NCI-MATCH cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment

ELSE PRESS RELEASES FROM THIS DATE:

Obesity a risk factor for stillbirth, especially at term

2024-03-04
Obesity is a risk factor for stillbirth, and the risk increases as pregnancy advances to term, according to a large study published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221450. The overall risk of stillbirth in pregnancy is approximately 0.4% in Canada. "Our findings suggest that an earlier delivery date may help reduce the risk of stillbirth for pregnant people with obesity," says lead author Dr. Naila Ramji, a high-risk pregnancy specialist in Fredericton, New Brunswick, and ...

Pioneering research reveals empathetic communication can help overcome vaccine hesitancy

2024-03-04
An international study has shown for the first time how empathetic correction of misinformation among vaccine-hesitant patients can significantly improve attitudes towards vaccination – and potentially boost vaccine uptake. The research, led by the University of Bristol, also found this new style of communication could help build and maintain a positive relationship with health professionals, increasing trust and public confidence. With the UK currently facing a growing measles outbreak, fuelled by declining rates of the Measles, ...

Rare astrolabe discovery reveals Islamic – Jewish scientific exchange

Rare astrolabe discovery reveals Islamic – Jewish scientific exchange
2024-03-04
The identification of an eleventh century Islamic astrolabe bearing both Arabic and Hebrew inscriptions makes it one of the oldest examples ever discovered and one of only a handful known in the world. The astronomical instrument was adapted, translated and corrected for centuries by Muslim, Jewish and Christian users in Spain, North Africa and Italy.   Dr Federica Gigante, from Cambridge University’s History Faculty, made the discoveries in a museum in Verona, Italy, and published them today in the journal Nuncius. Dr Gigante first came across a newly-uploaded ...

Sleep apnea symptoms linked to memory and thinking problems

2024-03-03
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, SUNDAY, MARCH 3, 2024 MINNEAPOLIS – People who experience sleep apnea may be more likely to also have memory or thinking problems, according to a preliminary study released today, March 3, 2024, that will be presented at the American Academy of Neurology’s 76th Annual Meeting taking place April 13–18, 2024, in person in Denver and online. The study shows a positive association but did not determine whether  sleep apnea causes cognitive decline. Sleep ...

Nanoscale topcoat can turbocharge supported gold nanoparticle catalysts

Nanoscale topcoat can turbocharge supported gold nanoparticle catalysts
2024-03-02
Tokyo, Japan – Researchers from Tokyo Metropolitan University have developed a way to add single nanosheets of mixed metal oxide to gold nanoparticles supported on silica to enhance their catalytic activity. Converting carbon monoxide to carbon dioxide, they found that the temperature required for the reaction was greatly reduced, with significant improvements over existing methods for coating gold/silica structures. The method paves the way for the development of a wide range of new high-performance catalysts.   Gold nanoparticles, particles less than five nanometers in diameter, are known to be excellent catalysts ...

Beyond the ink: Painting with physics

Beyond the ink: Painting with physics
2024-03-02
Falling from the tip of a brush suspended in mid-air, an ink droplet touches a painted surface and blossoms into a masterpiece of ever-changing beauty. It weaves a tapestry of intricate, evolving patterns. Some of them resemble branching snowflakes, thunderbolts or neurons, whispering the unique expression of the artist's vision. Okinawa Institute of Science and Technology (OIST) researchers set out to analyse the physical principles of this fascinating technique, known as dendritic painting. They took inspiration from the artwork ...

Only 9 percent of older Americans were vaccinated against RSV before the disease hit this fall and winter

2024-03-02
A new study from the Texas A&M University School of Public Health found that only 9 percent of older Americans had been vaccinated against respiratory syncytial virus (RSV) prior to this fall and winter, despite the threat of increased rates of hospitalization and deaths nationwide from the virus. “RSV—along with COVID-19 and influenza—form the current ‘tripledemic’ found across the United States this fall and winter,” said Simon Haeder, PhD, the study’s author. “While the elderly, as well as the very young and those with chronic health conditions, typically are affected ...

Evolution-capable AI promotes green hydrogen production using more abundant chemical elements

Evolution-capable AI promotes green hydrogen production using more abundant chemical elements
2024-03-02
1. A NIMS research team has developed an AI technique capable of expediting the identification of materials with desirable characteristics. Using this technique, the team was able to discover high-performance water electrolyzer electrode materials free of platinum-group elements—substances previously thought to be indispensable in water electrolysis. These materials may be used to reduce the cost of large-scale production of green hydrogen—a next-generation energy source. 2. Large-scale production of green ...

In wake of powerful cyclone, remarkable recovery of Pacific island’s forests

In wake of powerful cyclone, remarkable recovery of Pacific island’s forests
2024-03-01
After one of the most intense cyclones in world history tore through the Pacific island of Tanna in Vanuatu, new research led by the University of Hawaiʻi at Mānoa showed the resilience of the island’s forests. In the Pacific islands, climate change is expected to increase the intensity and frequency of cyclones, causing huge potential risks to forests and the people who depend on them. In March 2015, Cyclone Pam touched down on the island of Tanna as the strongest Pacific island cyclone in history ...

PSU study sheds light on 2020 extreme weather event that brought fires and snow to western US

2024-03-01
The same weather system that led to the spread of the devastating Labor Day wildfires in 2020 brought record-breaking cold and early-season snowfall to parts of the Rocky Mountains. Now, new research from Portland State is shedding light on the meteorology behind what happened and the impacts of such an extreme weather event. “It’s really interesting to see such an amplified pattern result in opposing extremes in the Pacific Northwest and the Rocky Mountains,” said Emma Russell, a master’s student in geography ...

LAST 30 PRESS RELEASES:

Echidnapus identified from an ‘Age of Monotremes’

Semaglutide may protect kidney function in individuals with overweight or obesity and cardiovascular disease

New technique detects novel biomarkers for kidney diseases with nephrotic syndrome

Political elites take advantage of anti-partisan protests to disrupt politics

Tiny target discovered on RNA to short-circuit inflammation, UC Santa Cruz researchers find

Charge your laptop in a minute? Supercapacitors can help; new research offers clues

Scientists discover CO2 and CO ices in outskirts of solar system

Theory and experiment combine to shine a new light on proton spin

PKMYT1, a potential ‘Achilles heel’ of treatment resistant ER+ breast cancers with the poorest prognosis

PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors (PARs)

Virginia Tech researcher creates new tool to move tiny bioparticles

On repeat: Biologists observe recurring evolutionary changes, over time, in stick insects

Understanding a broken heart

Genetic cause of rare childhood immune disorders discovered

With wobbling stars, astronomers gauge mass of 126 exoplanets and find 15 new ones

High H5N1 influenza levels found in mice given raw milk from infected dairy cows

Study finds discreet shipping used to sell e-cigarettes to minors

African scientists call for equitable research partnerships to advance microbiome research

How COVID-19 'breakthrough' infections alter your immune cells

Virginia Tech entomologist sheds light on 250-year-old mystery of the German cockroach

Advancing skin science: explore Skin Ageing & Challenges 2024 Strategic Topics in Malta this November

Controlling water, transforming greenhouse gases

MSK Research Highlights, May 24, 2024

ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans

ASCO: Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

Euclid space mission releases first scientific results and new images of the cosmos

Sociodemographic heterogeneity in the associations of social isolation with mortality

COVID-19 admission rates and changes in care quality in us hospitals

Preterm and early-term delivery after heat waves in 50 US metropolitan areas

Research spotlight: Virtual scribes reduced physicians’ time spent on electronic health records

[Press-News.org] NCI-MATCH cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment
Trastuzumab-pertuzumab is FDA-approved for patients with HER2-positive breast cancer, with minimal side effects. The NCI-MATCH precision medicine trial saw it shrink tumors in several other cancer types—a discovery that warrants further research.